Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + BR in Relapsed/Refractory CLL/SLL (HELIOS)
NCT01611090Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2012
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) comparing Placebo + BR with Ibrutinib + BR (2 arms). Primary endpoint: Progression-Free Survival up to 5 years. Started Sep 2012; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01611090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01611090.